A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- MediciNova notified of settlement in Sanofi Novartis litigation
- Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic Esophagitis
- Regeneron, Sanofi announce EC approval for Dupixent
- Sanofi’s Dupixent Shows Promise for Skin Disorder
- Sanofi says Beyfortus to be broadly available in more Canadian territories soon